resistance, were used (H275-mutated, M15I-mutated and V106I-N248D-N200S -triple 1 3 9 mutated NA plasmid); for H3N2, a sole mutated plasmid was used (R292K-mutated NA). (0.1% for QC1; 0.5% for QC2; 1% for QC3; 5% for QC4; and 10% for QC5). A mix of non- Mixes were then considered similarly to clinical samples for the rest of the study. Nucleic acids were extracted from samples using an automatic extraction platform (Nuclisens Madison, WI, USA) were incubated for 90 min at 37°C. Enzymatic reaction was then stopped
by an immediate purification using a magnetic bead system (NucleoMag® NGS Clean-up and 1 5 5
Size Select, Macherey-Nagel, Düren, Germany) using a 0.5X ratio to limit potential small 1 5 6
RNA presence.
5 7
Viral nucleic acids were amplified differentially depending on the viral type determined a multi-segment RT-PCR as described by Zhou et al. in 2009 (19) . For IBV-positive samples, Inhibitor (Promega Corporation) to enhance PCR products quantities.
Correct amplification was verified by agarose gel electrophoresis (1%) and samples with no using NucleoMag ® NGS Clean-up and Size Select (Macherey-Nagel) quantified first by with HS DNA quantification kit (LifeTechnologies).
6 8
Library preparation and sequencing
The library was constructed using the Nextera™ XT DNA library kit (Illumina, San Diego,
CA, USA) according to manufacturer's recommendations. Briefly, samples were fragmented
and tagged during the same process by a Nextera XT transposase (Illumina). Then, these adaptor-ligated DNA fragments were linked to the barcode and adaptors combination by a 96, and then diluted in hybridation buffer. These multiplex samples were then denatured using 1 7 7
NaOH and TrisHCl before loading on the NextSeq500 mid-output cartridge. After the 2x150
bp NextSeq paired-end sequencing run, data were base called and reads were collected and
assigned to a sample when showing the same barcode combination, which generated Illumina
FastQ files.
Sequencing data
The reads obtained on the sequencing platform were submitted to NCBI's Sequence Read
Archive and can be found under project numbers SRP140895 (samples) and SRP137044
(quality control).
8 5
Bioinformatic analysis
Briefly, the downstream analysis of the resulting Illumina FastQ files included: quality and 1 8 7
read cleaning pre-processing, mapping to a generated reference and diversity analysis through read-pairs shorter than 50 bases were removed using cutadapt (v0.4.4) (21). Mapping to were verified on their hemagglutinin homology with subtype references. Consensus sequences were generated to obtain the closest possible mapping reference allowing a new mapping processing. SNV calls were generated using naive variant caller (Biomina Galaxy platform) only filtering low quality bases (score<Q20) (23). End-user workable files, presenting validated SNVs and segment diversity, were generated using a homemade vcf analysis tool written in python 1 9 7 (available upon request). Validation of these SNVs relied on stringent criteria determined on On the 692 clinical files screened for this study, 14 patients hospitalized from 2010 to 2015
with two or more respiratory samples (median number of samples per patient: 2; sampling
delay between two samples from one to 14 days) tested positive for IAV or IBV were
included for a total of 95 patient-days (i.e. a patient followed for a day). Clinical and
biological data are summarized in the respiratory group). All patients were sampled at least twice and one was sampled three and 10 NPA); others were taken from the lower respiratory tract (7 samples; 6 BAL and 1
Determination of SNV frequency threshold
A total of 51 artificial mixes of plasmids were sequenced to validate the process (27 H1N1- sample sequenced for diversity analysis, at least one of these mixes of plasmids were
sequenced. This allowed extensive performance validation of intra-run performance and inter-
run reproducibility. Variants were detected in artificial mixes that included 10%, 5%, and 1% 44,000X for H3N2-like plasmids) found that there was no cross-contamination or 2 4 0 bioinformatics bias (Table 2) . Sufficient depth to allow statistical analyses was observed in
clinical samples (Supplementary figure S1).
4 2
All expected variants were detected for mixes containing 5% and 10% mutants (as 2 4 3 summarized in Table 2 ). Sensitivity of detection decreased with the expected frequency of the 2 4 4 mutation; resulting from inconstancies in detection for H1N1 (11 absence of detection on 25 reproducibility.
5 6
In light of these results, the detection threshold of 5% was used for the rest of the study. Influenza genome hotspots and coldspots
In IAV samples and using a 5% filter, 183 amino-acid coordinates (183/4,246, 4.31%) were 2 5 9
identified as having at least one mutation during clinical course, independently of the clinical 2 6 0 outcome (Table 3. ). Prevalence of these residues represented less than 5% of all residue 2 6 1 coordinates (from 3.16% for PA-coding segment to 6.61% for NA-coding segment, 2 6 2 independently from oseltamivir treatment). There was no significant difference in viral 2 6 3 number between segments (p>0.05).
6 4
As schematized in the Supplementary figure S2 , hotspots (defined as regions with at least twice the mean mutation rate of the considered segment) were significantly more frequent in 2 6 6 two of the eight major proteins (61/469 residues, 13.0% of the NA-coding segment; 21/229 2 6 7 residues, 9.17%, of the NS1-coding segment; versus 170/4246 residues, 4.00% for the whole samples per patient is represented in Supplementary figure S3.
7 7
To overcome possible bias associated with the clinical non-standardized nature of sequenced
samples, a statistical analysis between diversity and Ct was performed and did not find any between diagnosis Ct and diversity observed after sequencing (p>0.05). in Figure 4 ). Diversity was significantly lower in early than in late samples (mean difference:
2.55; p<0.05) for segment 3 (PB2-coding segment; Figure 4a ). For this segment, there was
significantly greater diversity in the neurological group in early samples than in both early 2 9 4 and late samples in the respiratory groups (mean differences: 6.44 and 7.33, respectively; 2 9 5 p<0.05) and for late samples in the mild group (mean difference 8.00; p<0.05, Figure 4b ). On the NS1-coding segment, diversity was not significantly different in early and in late samples for segment 8 (Figure 4c ). On this segment, significant differences were observed between 2 9 8 diversity in specimens sampled early in the clinical course of mild-group patients and of
severe-group patients (mean difference 5.00 and 6.08; p<0.05 and p<0.01 for comparison with 3 0 0 respiratory and neurological groups respectively). Moreover, a very significant difference was
observed between early and late diversity for mild-group patients (mean difference 6.33; 3 0 2 p<0.01; Figure 4d ). Analyses performed using a 1%-threshold for SNV calling found similar This study is the first, to the best of our knowledge, to describe influenza virus diversification 3 0 6 over time using clinical specimens sampled in immunocompetent patients and ultra-deep 3 0 7
sequencing.
Before the emergence of UDS, "classical" Sanger sequencing did not allow deep
characterization of these viral populations, due to insufficient depth of sequencing. At required to valid these processes (32). As UDS enables sequencing of several gigabases of coverage of all eight genomic segments in a single reaction to allow diversity analyses. The expected mutations were observed using a frequency threshold of 5% for SNV variant calling.
Using only two different plasmids, a similar approach defined a frequency threshold of 2%,
but as described by the authors the pipeline used does not take strand bias into account, was observed using a threshold of 1%) (25,34). Furthermore, plasmids are a more accurate
method to evaluate performance of NGS than whole viruses isolated in plaque assays as these 3 2 8
contain confounding mutations introduced during replication (35). It is important to note that,
herein, observed differences remained the same independently from the frequency filter that
was applied. Because the frequency threshold chosen has to be inversely related to the depth interest to compare samples sequenced using the same method, which is of interest for future In the present study, respiratory specimens were limited to those sampled from description of a baseline state of viral diversity without identifiable confounding factor. This baseline diversity has already been described as resulting from a bottleneck in studies between early and late diversity in patients with mild influenza, no significant difference was 3 4 2 found for those with severe disease either in the neurological or respiratory group. This 3 4 3 difference suggests that diversification could be considered as a virulence factor for influenza,
as has been suggested for Coxsackie virus, and as described in a poliovirus mouse model, and
for Foot-and-Mouth Disease virus (8, 37, 38) . Moreover, this result also supports the potential
value of an engineered virus with high fidelity polymerase to improve vaccine effectiveness 3 4 7
(10). Indeed, responsible for less severe manifestations, less diversified viruses obtained using
these polymerases would enhance vaccine effectiveness without a dramatic increase in 3 4 9 morbidity rates. Conversely, the dramatic decrease of diversity observed for mild influenza is reflects that the error threshold was exceeded that led to extinction of the viral population. processes constrain the within and between host evolution of influenza virus. eLife. Opin Virol. 2018;28:20-5. Microbiol. 2017;2:17088. 
